Compare DOYU & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOYU | CDXS |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Major Chemicals |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.0M | 141.8M |
| IPO Year | 2019 | 2008 |
| Metric | DOYU | CDXS |
|---|---|---|
| Price | $4.98 | $1.61 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 28.3K | ★ 3.4M |
| Earning Date | 03-25-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | N/A | $6.35 |
| Revenue Next Year | N/A | $16.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $4.28 | $0.96 |
| 52 Week High | $9.34 | $3.87 |
| Indicator | DOYU | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 46.88 | 57.32 |
| Support Level | $4.39 | $1.57 |
| Resistance Level | $5.38 | $1.86 |
| Average True Range (ATR) | 0.21 | 0.19 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 52.87 | 28.47 |
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.